Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-DCVAX
- Development stage
- Preclinical
- Lead developer
- Cell BioEngines
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
Neo-DCVAX (CBE 201) is an autologous Type 1 dendritic cell (DC1) vaccine being developed by Cell BioEngines for the treatment of solid tumor malignancies. The therapy utilizes the company's proprietary cell engineering platform to generate highly potent dendritic cells designed to present neoantigens and stimulate a robust, tumor-specific T-cell response. By polarizing dendritic cells toward a Type 1 phenotype, the vaccine aims to enhance the production of IL-12 and promote the activation of cytotoxic T lymphocytes (CTLs) and Th1 cells within the tumor microenvironment. It is currently in the preclinical stage of development.
- Other names
- Neo-DCVAXCBE 201CBE201CBE-201
02
Targets
pMHC-I (Peptide–MHC class I complex)MHC-I/II (Major histocompatibility complex class I and class II molecules (MHC-I and MHC-II))
Beyond the preview
Go deeper on Neo-DCVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-DCVAX.